Old Web
English
Sign In
Acemap
>
authorDetail
>
Carol Toris
Carol Toris
University of Nebraska Omaha
Intraocular pressure
Pharmacology
Anatomy
cGMP-specific phosphodiesterase type 5
Diabetes mellitus
3
Papers
11
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma
2020
Investigative Ophthalmology & Visual Science
Francesco Impagnatiello
Tomas Navratil
Carol Toris
Michael V W Bergamini
Stefania Brambilla
Corinna Galli
Nicoletta Almirante
Elena Bastia
Show All
Source
Cite
Save
Citations (0)
Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma
2020
Investigative Ophthalmology & Visual Science
Elena Bastia
Carol Toris
Michael V W Bergamini
Stefania Brambilla
Corinna Galli
Nicoletta Almirante
Francesco Impagnatiello
Show All
Source
Cite
Save
Citations (0)
FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys.
2014
Drug Development Research
Najam A. Sharif
Parvaneh Katoli
Daniel Scott
Linya Li
Curtis Kelly
Shouxi Xu
Shahid Husain
Carol Toris
Craig E. Crosson
Show All
Source
Cite
Save
Citations (11)
1